India's Ranbaxy Sees Generic Deal For Nexium Kicking Off This Year
This article was originally published in PharmAsia News
Executive Summary
A deal between Ranbaxy Laboratories and AstraZeneca for a generic version of the U.K.-based firm's proton pump inhibitor Nexium (esomeprazole) is set to take place by the end of this year, ending a delay of more than a year
You may also be interested in...
Biden COVID-19 Plan Would Grow Domestic Manufacturing Base
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
People On The Move: Appointments At Sanofi, Enzymatica And Bayer
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
Trust, Innovation And Growth – Three Priorities For The Global Self-Care Industry In 2021
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."
Need a specific report? 1000+ reports available
Buy Reports